Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06319820 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

Study acronym: MoonRISe-1
StatusRecruiting
PhasePhase 3
Started2024-04-18
View on ClinicalTrials.gov ↗
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.

Amendment record

Amended 37 times since 2024-03-13; most recent filed 2026-08-27. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-08-27
Amendment Study Status, Contacts/Locations v37
2026-07-02
Amendment Study Status, Contacts/Locations v36
2026-06-04
Amendment Study Status, Contacts/Locations v35
2026-05-07
Amendment Study Status v34
2026-04-09
Amendment Study Status, Contacts/Locations v33
2026-03-12
Amendment Study Status, Contacts/Locations v32
2026-02-12
Amendment Study Status, Study Design, Contacts/Locations v31
2026-01-23
Amendment Study Identification, Study Status, Conditions, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v30
2025-12-18
Amendment Study Status, Contacts/Locations v29
2025-12-04
Amendment Study Status, Study Design, Contacts/Locations v28
2025-11-06
Amendment Study Status, Contacts/Locations v27
2025-10-09
Amendment Study Status, Contacts/Locations v26
2025-09-11
Amendment Study Status, Study Design, Contacts/Locations v25
2025-08-14
Amendment Study Status v24
2025-07-18
Amendment Study Status, Contacts/Locations v23
2025-07-17
Amendment Study Status v22
2025-06-20
Amendment Study Status, Contacts/Locations v21
2025-05-22
Amendment Study Status, Contacts/Locations v20
2025-04-25
Amendment Study Status, Contacts/Locations v19
2025-04-24
Amendment Study Status v18
2025-03-28
Amendment Study Status, Contacts/Locations v17
2025-03-27
Amendment Study Status v16
2025-02-28
Amendment Study Status, Contacts/Locations v15
2025-02-03
Amendment Study Identification, Study Status, Eligibility, Contacts/Locations, IPDSharing v14
2025-01-09
Amendment Study Status, Contacts/Locations v13
2025-01-08
Amendment Study Status v12
2024-12-04
Amendment Study Status, Contacts/Locations v11
2024-12-03
Amendment Study Status v10
2024-10-23
Amendment Study Status, Contacts/Locations v9
2024-10-08
Amendment Study Status, Contacts/Locations v8
2024-09-10
Amendment Study Status, Contacts/Locations v7
2024-08-13
Amendment Study Status, Contacts/Locations v6
2024-07-16
Amendment Study Status, Contacts/Locations v5
2024-06-18
Amendment Study Status, Contacts/Locations v4
2024-05-21
Amendment Study Status, Contacts/Locations v3
2024-04-23
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
2024-03-26
Amendment Study Status, Contacts/Locations v1
2024-03-13
Original filing
Trial Details
NCT Number NCT06319820
Lead Sponsor Janssen Research & Development, LLC
Conditions Non-Muscle Invasive Bladder Neoplasms
Enrollment 641 participants
Start Date 2024-04-18
Primary Completion 2028-06-28 (estimated)
Study Completion 2032-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-28